Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
August 14, 2018

Sorrento treats first patient in PTVA-OA-001 trial of RTX

Sorrento Therapeutics has treated the first patient enrolled in the PTVA-OA-001 trial and is set to continue the study after the data monitoring committee (DMC) found no safety concerns associated with the drug in a scheduled safety assessment.

Sorrento Therapeutics has treated the first patient enrolled in the PTVA-OA-001 trial and is set to continue the study after the data monitoring committee (DMC) found no safety concerns associated with the drug in a scheduled safety assessment.

The PTVA-OA-001 trial is a Phase lb study to investigate the safety and define the maximally tolerated dose of resiniferatoxin (RTX) administered in the knee joint for the reduction of moderate-to-severe pain signal intensity associated with osteoarthritis.

The multicentre, placebo-controlled trial is expected to enrol 40 patients in up to five dose level cohorts.

PTVA-OA-001 features a dose-escalation design, where cohorts of patients will receive increasing doses of resiniferatoxin until the maximum tolerated dose (MTD) is achieved.

The trial’s primary endpoint is to analyse the safety of resiniferatoxin and identify the recommended Phase ll dose.

“We believe resiniferatoxin has the potential to adequately address this need and may help limit chronic use of other pain medications, including opioids.”

The secondary endpoint of the trial is to evaluate the preliminary efficacy of resiniferatoxin measured by assessing changes in the intensity of pain using the WOMAC Index.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

Sorrento expects to stop the study once a clearly effective dose or a maximum tolerated dose is reached prior to the highest dose scheduled to be received.

The trial is scheduled to be completed within the first half of next year.

Sorrento Therapeutics chief medical officer Dr Jerome Zeldis said: “Joint pain affects over 30 million patients in major markets, half of which suffer from knee osteoarthritis pain.

“A clear unmet need for a single-administration, long-lasting, non-opioid and non-steroidal pain control solution exists for this degenerative joint disease.

“We believe resiniferatoxin has the potential to adequately address this need and may help limit chronic use of other pain medications, including opioids.”

Resiniferatoxin is a non-opioid, afferent nerve ablating drug candidate currently under development by Sorrento.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU